Class II Category Based On "Safety And Performance" Still Priority For CDRH
This article was originally published in The Gray Sheet
Executive Summary
Amending the Class II device definition to require demonstration of "safety and performance" rather than substantial equivalence is high on the FDA Center for Devices and Radiological Health's list of priorities for discussion during the first round of renegotiation of the FDA Modernization Act, according to topsiders at the device center.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.